Cyclacel Pharmaceuticals, Inc. (CYCC)
Chart Events
Performance Outlook
| Previous Close | 3.8500 |
| Open | 3.8700 |
| Bid | 3.7000 x 800 |
| Ask | 3.7900 x 900 |
| Day's Range | 3.7100 - 3.8700 |
| 52 Week Range | 3.6700 - 11.4200 |
| Volume | 12,825 |
| Avg. Volume | 115,614 |
| Market Cap | 37.008M |
| Beta (5Y Monthly) | 1.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6570 |
| Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.00 |
Fair Value
Related Research
- Cyclacel Pharmaceuticals, Inc.Weekly Stock ListVickers Stock Research, a subsidiary of Argus Research Group, tracks and analyzes insider trading and institutional ownership trends. Form 13-Fs are due 45 days after the end of calendar quarters, and have now come in from 2Q21. We like to review the 13Fs of the major activist investors, including Carl Icahn, Trian Fund Management, Jana Partners, and ValueAct Holdings, among others. Activist investing has evolved in recent years and is now less about generating a short-term return on an underpriced stock and more about achieving long-term returns through an active management/investor partnership. Here are some recent new purchases and key holdings of activist investors, according to Vickers.RatingFair ValueEconomic Moat7 days agoArgus Research
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update
- Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia -- Cash Runway to Early 2023 -- Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET - BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2021. The quarter’s business high
- GlobeNewswire
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed StudyBERKELEY HEIGHTS, N.J., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients wit
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Third Quarter 2021 Financial Results and Provide Business Update
BERKELEY HEIGHTS, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter financial results and provide a business update on Wednesday, November 10, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Conference ID:
